Syntara Limited has released a press release.
LOXL2 Program Attracts Strong Partner Interest at BIO18
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Syntara
- Quarterly Shareholder Update - March 2018
- Pharmaxis Earns A$15 Million Milestone Payment
- New Australian PBS Listing for Brocnhitol
- Pharmaxis Acquires Control, Increases Stake in LOXL2 Program
- Boehringer Initiating Phase 2a Study Diabetic Retinopathy
Later from Syntara
- Quarterly Shareholder Update - June 2018
- Trading Halt Announcement - System Upgrade
- Capital Raising Presentation
- FDA Factory Approval and Relaunch of Aridol in US Market
- Positive Phase 1 Results of Phase 1 Study - LOXL2 Inhibitor
Follow Syntara into a list and get an email when it puts out news.
Follow Syntara